U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07806630) titled 'SHORTened Duration of TAMoxifen' on Sept. 01.
Brief Summary: The purpose of this study is to learn whether a shorter-duration, low-dose tamoxifen regimen can reduce the risk of developing breast cancer or breast cancer recurrence in post-menopausal women who are at increased risk for breast cancer.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
High Risk for Invasive Breast Cancer
Intervention:
DRUG: Tamoxifen
Low-dose tamoxifen will be administered at 10 mg orally every other day for 18 months.
DRUG: Tamoxifen (Nolvadex)
Low dose Tamoxifen for 18 months.
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor...